TrialESMO open2023
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA).
L Cortesi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
TrialESMO open2023
L Cortesi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.